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Summary
 
The binding of immunoglobulin E (IgE) to high affinity IgE receptors (Fc
 
e
 
RI) expressed on
the surface of mast cells primes these cells to secrete, upon subsequent exposure to specific an-
tigen, a panel of proinflammatory mediators, which includes cytokines that can also have im-
munoregulatory activities. This IgE- and antigen-specific mast cell activation and mediator
production is thought to be critical to the pathogenesis of allergic disorders, such as anaphylaxis
and asthma, and also contributes to host defense against parasites. We now report that exposure
to IgE results in a striking (up to 32-fold) upregulation of surface expression of Fc
 
e
 
RI on
mouse mast cells in vitro or in vivo. Moreover, baseline levels of Fc
 
e
 
RI expression on perito-
neal mast cells from genetically IgE-deficient (IgE 
 
2
 
/
 
2
 
) mice are dramatically reduced (by
 
z
 
83%) compared with those on cells from the corresponding normal mice. In vitro studies in-
dicate that the IgE-dependent upregulation of mouse mast cell Fc
 
e
 
RI expression has two com-
ponents: an early cycloheximide-insensitive phase, followed by a later and more sustained com-
ponent that is highly sensitive to inhibition by cycloheximide. In turn, IgE-dependent
upregulation of Fc
 
e
 
RI expression significantly enhances the ability of mouse mast cells to re-
lease serotonin, interleukin-6 (IL-6), and IL-4 in response to challenge with IgE and specific
antigen. The demonstration that IgE-dependent enhancement of mast cell Fc
 
e
 
RI expression
permits mast cells to respond to antigen challenge with increased production of proinflamma-
tory and immunoregulatory mediators provides new insights into both the pathogenesis of al-
lergic diseases and the regulation of protective host responses to parasites.
 
M
 
ast cells are widely distributed in vascularized tissues
and serosal cavities, where they can function as ef-
fector cells in IgE-dependent immune responses (1–8). In-
deed, IgE- and antigen-dependent activation of mast cell
mediator secretion is thought to contribute significantly to
both the pathogenesis of allergic diseases (1, 4–8) and the
expression of acquired immunity to infection with certain
parasites (1, 3).
Several lines of evidence, including the phenotype of
mice genetically engineered to lack expression of either the
Fc
 
e
 
RI 
 
a
 
 chain (9) or the FcR 
 
g
 
 chain (10), indicate that
mast cells (and basophils, circulating granulocytes that can
produce many of the same mediators as mast cells; refer-
ences 1–8) must display high affinity IgE receptors (Fc
 
e
 
RI)
on their surface in order to express significant IgE- and an-
tigen-specific effector function. Yet the factors that regu-
late the expression of Fc
 
e
 
RI on the surface of these effector
cells are incompletely understood (5, 6). Two groups inde-
pendently demonstrated that the level of Fc
 
e
 
RI expression
on circulating human basophils can exhibit a positive cor-
relation with the serum concentration of IgE (11–13).
However, the basis for this association was not determined.
Malveaux et al. (13) proposed two possible explanations for
their findings, i.e., a genetic association between serum IgE
and the number of basophil IgE receptors or, more likely,
in their view, the modulation of basophil receptor number
by the serum IgE concentration. Another possibility is that
some common factor (or factors), such as immunoregula-
tory cytokines, can influence both IgE levels and basophil
Fc
 
e
 
RI expression.
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There have been no reports that circulating levels of IgE
can influence the expression of Fc
 
e
 
RI on mast cells. How-
ever, two studies demonstrated that short-term incubation
of the rat basophilic leukemia cell line (RBL-2H3) with IgE
in vitro can result roughly in a doubling of the cells’ surface
expression of Fc
 
e
 
RI (14, 15). Based on an analysis of several
of its phenotypic characteristics, the RBL-2H3 cell line prob-
ably should be regarded as of mast cell, rather than baso-
phil, origin (16). The findings of Furuichi et al. (14) and
Quarto et al. (15) thus indicate that exposure to mono-
meric IgE in vitro can result in a modest increase in Fc
 
e
 
RI
expression in a long-term malignant mast cell line. These
studies also showed that this effect, which was insensitive to
inhibition by cycloheximide (14), probably largely reflected
IgE-dependent suppression of the elimination of Fc
 
e
 
RI
from the cell surface (14, 15). However, the relevance of
these observations to normal mast cells was not clear. More
importantly, it was not established whether IgE-induced
increases in Fc
 
e
 
RI expression resulted in enhanced respon-
siveness to IgE-dependent release of proinflammatory me-
diators.
In this report, we used in vitro, in vivo, and genetic ap-
proaches to examine whether IgE can directly regulate Fc
 
e
 
RI
expression on the surface of mouse mast cells. We found
that IgE can substantially upregulate Fc
 
e
 
RI expression on
mouse mast cells in vitro or in vivo, and showed that this
IgE-dependent enhancement of mouse mast cell Fc
 
e
 
RI ex-
pression, in turn, can significantly increase the ability of
these cells to release proinflammatory and immunoregula-
tory mediators in response to IgE-dependent activation.
 
Materials and Methods
 
Flow Cytometry of Mouse Peritoneal Mast Cells and In Vitro-derived
Mouse Mast Cells.
 
In the mouse, mast cells express two surface
receptors that can bind IgE, the high affinity receptor that binds
IgE monomers, Fc
 
e
 
RI, and Fc
 
g
 
RII/III, which can bind IgE im-
mune complexes (17, 18). By contrast, the low affinity IgE recep-
tor, CD23, appears to be restricted to cells other than mast cells
(e.g., B cells) in the mouse (18, 19). Because our studies em-
ployed monomeric IgE, IgE binding to mouse mast cells under
the conditions of our experiments reflects largely, if not entirely,
binding of IgE to Fc
 
e
 
RI (18). Nevertheless, for flow cytometric
analysis of unfractionated freshly isolated mouse peritoneal cells (20),
we preincubated the cells with B3B4 (21) and 2.4G2 (18, 22)
mAbs for 15 min to block low affinity binding of IgE or other
subsequent antibodies to CD23 (on B cells, reference 19) or Fc
 
g
 
-
RII/III (on mast cells or monocytes/macrophages, references 18,
22), respectively. The cells were then incubated at 4
 
8
 
C with a
mouse IgE anti-DNP mAb (reference 23, 10 
 
m
 
g/ml) for 50 min,
to saturate fully any Fc
 
e
 
RI expressed by these cells (18), and then,
simultaneously, for the last 25 min, with a biotinylated rat anti–
mouse c-kit antibody (PharMingen, San Diego, CA, at 15 
 
m
 
g/ml).
After washing once in DMEM (GIBCO BRL, Gaithersberg, MD)
supplemented with 5% FCS (Sigma Chemical Co., St. Louis,
MO), cells were stained with FITC–rat anti–mouse IgE antibody
(PharMingen, at 10 
 
m
 
g/ml) and PE–streptavidin (Sigma Chemi-
cal Co., at 14 
 
m
 
g/ml) for 25 min at 4
 
8
 
C. Stained cells were ana-
lyzed using a FACSCalibur
 
Ò
 
 (Becton Dickinson, San Jose, CA).
Autofluorescent cells (primarily macrophages) were rejected to
identify mast cells (IgE
 
1
 
, c-kit
 
1
 
) clearly. 20,000 peritoneal cells in
each sample were analyzed, and at least 100 mast cells were stud-
ied to calculate the median value of fluorescence intensity. We
confirmed that the gated IgE
 
1
 
, c-kit
 
1
 
 cells were exclusively mast
cells by staining cytocentrifuge preparations of the sorted cells
with May-Grünwald-Giemsa stain and then examining them by
light microscopy at 
 
3
 
400.
An instrument setting of the flow cytometer that was appropri-
ate for analysis of peritoneal cells was determined in the first ex-
periment and was used for all such analyses throughout this study.
The median values of fluorescence intensity of mast cells were
converted to the numbers of molecules of equivalent soluble flu-
orochrome units (MESF)
 
1
 
 using Quantum 25 microbeads (Flow
Cytometry Standards Co., San Juan, PR) on each day an experi-
ment was performed, as per the specifications of the manufac-
turer.
For cell culture before flow cytometry, unfractionated perito-
neal cells (purity of mast cells assessed by May-Grünwald-Giemsa
stain 3–5%) were cultured at 5 
 
3
 
 10
 
5
 
 cells/ml in DMEM (GIBCO)
supplemented with 10% FCS, 50 ng/ml rat recombinant stem cell
factor (rrSCF) (Amgen, Thousand Oaks, CA, reference 20), 2 mM
L-glutamine, and antibiotics (penicillin/streptomycin).
Bone marrow–derived cultured mouse mast cells (BMCMCs)
were generated by culturing femoral bone marrow cells of BALB/c
mice (Charles River Laboratory, Wilmington, MA) or genetically
engineered IgE 
 
2
 
/
 
2
 
 mice (reference 24, third generation back-
cross into BALB/c) or corresponding normal (IgE 
 
1
 
/
 
1
 
) BALB/c
mice, or WBB6F
 
1
 
 
 
1
 
/
 
1
 
 mice (Jackson Laboratories, Bar Harbor,
ME), in 20% WEHI-3 cell supernatant–conditioned medium for
4 to 6 wk (25). For flow cytometry, cells were preincubated with
2.4G2 antibody (as above) and then with ascites IgE mAb (as above)
or affinity-purified mouse anti-DNP IgE mAb (clone SPE-7;
Sigma), at 10 
 
m
 
g/ml, for an additional 50 min at 4
 
8
 
C. After wash-
ing, cells were stained with FITC–anti-IgE antibody for 25 min.
At least 10,000 BMCMCs were analyzed to obtain each MESF
value. The flow cytometry setting for BMCMCs was not changed
throughout this study.
Preparations of peritoneal mast cells or bone marrow–derived
mast cells were incubated for up to 4–6 d with various concentra-
tions of ascites containing mouse IgE anti-DNP (stock concentra-
tion 
 
5
 
 506 
 
m
 
g IgE/ml) (23) or IgG2a (Sigma) mAbs, or affinity-
purified mouse IgE or IgG2a mAbs (clones SPE-7 and UPC 10,
respectively; Sigma), before flow cytometry or analysis of media-
tor release, as described in Results. Before being used for flow cy-
tometric analysis (see above), cells that had been incubated with
IgE or IgG2a mAbs for up to 4 d were washed (in DMEM with
5% FCS) once if they had been incubated in concentrations of
mAb of 
 
<
 
5.0 
 
m
 
g/ml and twice if they had been incubated with
concentrations of mAb of 
 
.
 
5.0 
 
m
 
g/ml.
 
Western Blot Analysis of Fc
 
e
 
RI 
 
b
 
 Chain in Mouse Mast Cells.
 
For Western blot analysis, 2.5 
 
3
 
 10
 
7
 
 of the same BMCMCs used
for flow cytometry (i.e., just before analysis, the cells were incu-
bated with excess IgE at 4
 
8
 
C to saturate their Fc
 
e
 
RI, see above)
were extracted in 0.2 M borate buffer containing 0.5% Triton X-100
and proteinase inhibitors (26) and postnuclear extracts were sub-
jected to immunoprecipitation with noncoated beads (preclear) and
then two times with anti-IgE–coated beads (10 
 
m
 
g affinity-puri-
 
1
 
Abbreviations used in this paper:
 
 BMCMCs, mouse bone marrow–derived
cultured mast cells; DNP-HSA, DNP human serum albumin; MESF,
molecules of equivalent soluble fluorochrome units; RBL cells, rat baso-
philic leukemia cells; rrSCF, recombinant rat stem cell factor
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; SCF,
stem cell factor. 
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fied rabbit anti-IgE per precipitation), to isolate surface-expressed
Fc
 
e
 
RI that had bound IgE. Immunoprecipitates were pooled, re-
solved by 10% SDS-PAGE under reducing conditions, and im-
munoblotted to Immubilon P (Millipore, Bedford, MA). No an-
tibodies suitable for selectively identifying the mouse Fc
 
e
 
RI 
 
a
 
chain have been described. Accordingly, Western blotting was
performed with the JRK anti-mouse Fc
 
e
 
RI 
 
b
 
 chain mAb (26).
 
Quantification of Mouse Mast Cell Mediator Release.
 
For measure-
ments of serotonin (5-hydroxytryptamine, 5-HT) release, BMC-
MCs (
 
.
 
95% purity) or peritoneal cells were incubated with as-
cites IgE at 10 
 
m
 
g/ml and [
 
3
 
H]5-HT (NEN, Boston, MA) at 2
 
m
 
Ci/ml for 2 h at 37
 
8
 
C, washed, and 5-HT serotonin release was
calculated as the percentage of total incorporated [
 
3
 
H]5-HT
present in the cell supernatant 10 min after stimulation with DNP
human serum albumin (DNP–HSA) (Sigma), the calcium iono-
phore A23187 (Sigma), or vehicle at 37
 
8
 
C (27). For IL-6 or IL-4
release, BMCMCs were sensitized with ascites IgE at 10 
 
m
 
g/ml
for 50 min at 4
 
8
 
C, and stimulated with DNP–HSA for 4 h at
37
 
8
 
C. IL-6 or IL-4 in the supernatants was measured using ELISA
kits (Endogen, Cambridge, MA).
 
Assessment of the Effect of Administration of IgE In Vivo on Mouse
Mast Cell Fc
 
e
 
RI Expression.
 
12–22-wk-old mice were used in
four separate in vivo experiments, two with BALB/c mice (data
combined in Fig. 7 
 
A
 
), one with untreated IgE 
 
2
 
/
 
2
 
 and corre-
sponding IgE 
 
1
 
/
 
1
 
 mice (Fig. 7 
 
B
 
), and one with antibody-
treated IgE 
 
2
 
/2 mice (Fig. 7 C). Purified mouse IgG2a mAb
(Sigma, clone UPC 10) and mouse anti-DNP IgE mAb (Sigma,
clone SPE-7) were dialyzed to remove NaN3, centrifuged at
100,000 g for 1 h at 48C, and filtered before use. For i.v. treat-
ment, IgG2a or IgE (100 mg in 0.24 ml PBS) or 0.24 ml of PBS
alone was administered to each mouse daily by tail vein. Blood
was obtained at time of death (z18 h after the last i.v. injection)
for measurement of total serum IgE concentration by ELISA (28).
For assay of serotonin release, peritoneal cells were incubated for
20 h in DMEM containing 10% FCS (27) and then sensitized
with IgE, labeled with [3H]5-HT, and stimulated with DNP–
HSA as described above.
Statistics. Unless otherwise specified, all data are expressed as
mean 6 SEM, and all differences between values were compared
by the two-tailed Student’s t test (unpaired).
Results
IgE Enhances FceRI Expression in Mouse Peritoneal Mast
Cells In Vitro. As assessed by flow cytometry to detect
binding of IgE (see Materials and Methods), we found that
the baseline levels of FceRI expression on the surface of
BALB/c mouse peritoneal mast cells, identified as an IgE1,
c-kit1 subpopulation of unfractionated peritoneal cells (Fig. 1
A), were greatly enhanced, in a concentration- (Fig. 1, B and
C) and time- (Fig. 1 D) dependent manner, upon incubation
of the cells in vitro with a mouse monoclonal IgE antibody.
Moreover, FceRI expression progressively diminished when
peritoneal mast cells were incubated in vitro without added
IgE (Fig. 1 D). As a result, levels of FceRI expression in
peritoneal mast cells incubated for 6 d with IgE at 5 mg/ml
(i.e., in the range observed in the serum of parasite-infected
mice, reference 28) were 20-fold higher than those in cells
incubated for 6 d without IgE (Fig. 1 D). And mast cells in-
cubated for 4 d with a concentration of IgE (0.05 mg/ml)
comparable to that present in the serum of normal mice
(28, 29) had levels of FceRI expression that were 3.6-fold
those in cells incubated for 4 d without IgE (Fig. 1 C).
IgE Enhances FceRI Expression in Mouse Bone Marrow–
derived Cultured Mast Cells (BMCMCs) In Vitro. Unfraction-
ated peritoneal cells contain cells other than mast cells, some
of which may have influenced the effect of IgE on perito-
neal mast cell FceRI expression. Therefore, we next assessed
whether IgE also enhanced surface expression of FceRI in
essentially pure populations of immature mouse mast cells
derived in vitro from the bone marrow cells of IgE null
mice (IgE 2/2 mice) or the corresponding normal (IgE
1/1) BALB/c mice (24). Incubation with IgE (at 5 mg/ml)
resulted in a marked elevation (32-fold at day 4) in FceRI
expression in BMCMCs from IgE 1/1 mice (Fig. 2 A).
Essentially identical results were obtained in two additional
Figure 1. IgE enhances mouse peritoneal mast cell FceRI expression in
vitro in a time- and dose-dependent manner. (A) Identification of perito-
neal mast cells (gated, in box) by flow cytometry. Freshly isolated perito-
neal cells of retired breeder BALB/c mice were stained for the expression
of surface IgE receptor and c-kit. The gated cells were sorted and con-
firmed microscopically as 100% mast cells. (B–D) Regulation of surface
FceRI expression on peritoneal mast cells by ascites IgE ex vivo. (B) Peri-
toneal cells isolated from BALB/c mice were cultured for 4 d without IgE
or with IgE at 0.005, 0.05, or 5.0 mg/ml, incubated with excess IgE at
48C for 50 min to saturate mast cell FceRI, and then mast cell surface
FceRI expression was analyzed by flow cytometry. The background fluo-
rescence intensity of mast cells stained only for c-kit is also shown (no
anti-IgE). (C) Dose-dependent effect of IgE on surface FceRI expression
on peritoneal mast cells. Peritoneal cells from 5 BALB/c mice were com-
bined, cultured with or without IgE for 4 d, and analyzed by flow cytom-
etry for surface FceRI. MESF, molecules of equivalent soluble fluoro-
chrome units (see Materials and Methods). All data are mean 6 SEM
(n 5 3); ‡P 5 0.076, ***P ,0.0001 versus values for cells cultured with-
out IgE for 4 d. (D) Time course of changes in mast cell surface FceRI
expression in peritoneal cells (combined from 8 BALB/c mice) cultured
with or without IgE (5.0 mg/ml). All data are mean 6 SEM (n 5 3); **P
,0.001, ***P ,0.0001 versus values at the same time point for cells cul-
tured without IgE; †P ,0.05, ††P ,0.001, †††P ,0.0001 versus baseline
(day 0) value.666 IgE Enhances Mast Cell FceRI Expression
experiments with BMCMCs derived from IgE 2/2 mice
(data not shown), cell preparations which could not have
contained any source of endogenous mouse IgE (i.e., small
numbers of contaminating B cells).
Studies of cells transfected with either mouse FceRI, Fcg-
RII, or FcgRIII indicate that washing of the cells prior to
flow cytometric analysis does not significantly remove IgE
from FceRI, but can largely eliminate IgE or IgG from Fcg-
RII/FcgRIII (18). Accordingly, under the conditions of our
experiments, the IgE binding that we assessed by flow cytom-
etry reflected largely, if not entirely, the binding of IgE to
FceRI. Nevertheless, we used Western blotting to assess di-
rectly the extent to which the b chain of the FceRI was asso-
ciated with the BMCMC surface receptors that bound IgE
in our experiments. We found that the increase in IgE binding
that was detected by flow cytometry after incubation of
BMCMCs with IgE (at 5.0 mg/ml) for 21 h (z14-fold in-
crease versus BMCMCs that had not been incubated with
IgE) directly paralleled the amount of FceRI b chain obtained
from anti-IgE immunoprecipitates of these cells (an increase of
z17-fold versus control BMCMCs that had not been incu-
bated with IgE) (Fig. 2 B). These data provide further evidence
that the increased IgE-binding ability, which we detected on
the surface of mast cells that had been incubated with IgE,
indeed reflected increased surface expression of FceRI.
The mast cells that were incubated with the highest con-
centration of ascites IgE that was used routinely in our ex-
periments (i.e., 5 mg IgE/ml) were exposed to an z100-fold
dilution of the stock preparation of ascites. However, this
ascites-derived IgE preparation also significantly enhanced
mast cell FceRI expression even when tested at dilutions of
10,000- to 100,000-fold (to yield IgE concentrations of
0.05 or 0.005 mg/ml, respectively, e.g., see Fig. 1 C). Nev-
ertheless, to rule out the possibility that some constituent of
the ascites preparation other than IgE might have signifi-
cantly influenced our results, we incubated aliquots of the
same population of BALB/c BMCMCs for 4 d with either
ascites or affinity-purified IgE at 5 mg IgE/ml. We found
that either preparation of IgE markedly increased the
FceRI expression of the cells, and to essentially equivalent
levels (Fig. 3 A). Similar results were obtained in two addi-
tional experiments. By contrast, incubation of such BMCMCs
for 4 d with a mouse IgG2a mAb at 5 mg/ml had no de-
tectable effect on the cells’ surface expression of FceRI
(Fig. 3 A). A separate experiment gave the same result.
Figure 2. IgE enhances FceRI
expression in mouse bone mar-
row–derived cultured mast cells
(BMCMCs) in vitro. (A) Kinetics
of IgE-induced changes in sur-
face FceRI expression in BM-
CMCs. BMCMCs (always .95%
purity at 4–5 wk of culture) from
BALB/c (IgE 1/1) mice were
cultured with or without ascites
IgE (at 5.0 mg/ml) for the indi-
cated times. BMCMCs were
stained only for FceRI (with
FITC–IgE) and were analyzed
by flow cytometry using a differ-
ent instrument setting from that
in Fig. 1. All data are mean 6
SEM (n 5 3); ††P ,0.001, †††P
,0.0001 versus value at day 0.
(B) Upregulation of surface
FceRI protein by IgE. BMC-
MCs from IgE 2/2 mice were
cultured with or without ascites
IgE at 5 mg/ml for 21 h. After
sensitization with IgE at 10 mg/
ml for 30 min at 48C to saturate
surface FceRI, cells (n 5 2) were
analyzed by flow cytometry for
FceRI expression (see Materials
and Methods) and by immuno-
precipitation with anti-IgE and
Western blot (2.5 3 107 BMC-
MCs per lane) to assess levels of
surface-expressed FceRI b chain.
The difference of detected
FceRI expression between cells incubated with or without IgE was 14-
fold (by flow cytometry) and 17-fold (by Western blot), respectively.
Figure 3. Effects of various mouse IgE or IgG2a mAb preparations on
surface expression of (A–C) FceRI or (D) FcgRII/III in BMCMCs.
BALB/c BMCMCs were cultured with or without various concentra-
tions of mouse IgE or IgG2a mAb, either as diluted ascites preparations
(Ascites IgE or IgG2a) or as affinity-purified mAb preparations (Purified
IgE or IgG2a), for 4 d. Negative control in (A–C), cells cultured for 4 d
without IgE or IgG2a and then incubated with FITC–anti-IgE without
prior sensitization with IgE. (A) Incubation with either purified or ascites
IgE mAb (at 5.0 mg IgE/ml) resulted in an equivalent increase in the
FceRI expression of the cells, whereas cells incubated with either purified
IgG2a (at 5.0 mg/ml) or no antibody (none) exhibited similar low levels
of staining. (B and C) Incubation with high concentrations of purified (B)
or ascites (C) IgG2a resulted in little or no increase in BMCMC FceRI
expression, in comparison with positive control BMCMCs that had been
incubated with IgE at 5.0 mg/ml. (D) Incubation for 4 d with IgE or
IgG2a had little or no effect on the expression of FcgRII/III by BMCMCs.
Negative control in (D), cells cultured for 4 d without IgE or IgG2a and
then incubated with a rat IgG2b mAb of irrelevant specificity, instead of
the rat 2.4G2 anti–mouse FcgRII/III mAb, before staining with the PE–
anti-rat IgG antibody. The same results were obtained with ascites IgE
(shown) or purified IgE (not shown).667 Yamaguchi et al.
We also tested the effects of a 4-d incubation of BALB/c
BMCMCs with IgG2a at 5–1000 mg/ml. As expected, we
found that incubation with ascites IgE at 5 mg/ml markedly
increased BMCMC expression of FceRI (Fig. 3 B), whereas
either affinity-purified IgG2a, at 5 or 100 mg/ml (data not
shown) or 200 mg/ml (Fig. 3 B), or ascites IgG2a, at 5 or
100 mg/ml (data not shown) or 500 or 1,000 mg/ml (Fig. 3
C), had little or no effect on FceRI expression.
The effect of IgE on BMCMC FceRI expression ap-
peared to be specific, in that cells incubated for 4 d with
IgE at 5 mg/ml exhibited no detectable change in their sur-
face expression of FcgRII/III, as assessed by flow cytome-
try with the 2.4G2 antibody (Fig. 3 D). A 4-d incubation
of BMCMCs with purified IgG2a mAb (at 5 or 200 mg/
ml, data not shown) or ascites IgG2a mAb (at 1,000 mg/ml;
Fig. 3 D) also had little or no effect on the cells’ surface ex-
pression of FcgRII/III, as assessed by flow cytometry.
IgE-dependent Enhancement of Mast Cell FceRI Expression
Results in Enhancement of IgE-dependent Mast Cell Mediator
Release. To assess the functional significance of IgE-depen-
dent upregulation of mast cell FceRI expression, we incu-
bated BALB/c BMCMCs with 0, 0.005, or 5 mg/ml of IgE
for 4 d, then passively sensitized the cells with excess mon-
oclonal anti-DNP IgE (10 mg/ml) for 2 h, and then chal-
lenged the cells with various concentrations of specific anti-
gen (DNP–HSA) and measured release of the cytoplasmic
granule-associated mediator serotonin (5-HT) and the cy-
tokines, IL-6 and IL-4. As shown in Fig. 4, the IgE-induced
enhancement of FceRI expression (Fig. 4 A) was associated
with a significantly enhanced functional responsiveness to
antigen stimulation, as assessed either by 5-HT release (Fig.
4 B) or IL-6 (Fig. 4 C) or IL-4 (Fig. 4 D) production. The
results shown in Fig. 4 are representative of those obtained
in three other experiments in which we assessed 5-HT re-
lease and one other experiment in which we assessed IL-6
and IL-4 release.
Notably, IgE-dependent enhancement of mast cell FceRI
expression both decreased the concentration of antigen re-
quired to elicit IgE-dependent mediator release and mark-
edly increased mediator secretion at a given antigen con-
centration (Fig. 4, B–D). For example, when challenged
with antigen at 30 ng/ml, BMCMCs that had been incu-
bated for 4 d with IgE at 5.0 mg/ml exhibited z60%
greater specific release of 5-HT (Fig. 4 B) and z6-fold
greater release of IL-6 (Fig. 4 C) than did mast cells which
had been incubated for 4 d with IgE at 0.005 mg/ml. The
effect on IL-4 production was especially striking, in that
the only cells which exhibited detectable release of IL-4
upon challenge with specific antigen were those which had
been incubated for 4 d with IgE at 5.0 mg/ml (Fig. 4 D).
The same finding was obtained in an additional experiment
with BMCMCs derived from IgE 2/2 mice (data not
shown).
Figure 4. IgE-induced enhancement of mouse BMCMC FceRI ex-
pression increases the ability of these cells to release mediators in response
to IgE and specific antigen. Effects of IgE-induced changes in BMCMC
FceRI expression (A) on IgE- and antigen-dependent release of (B) sero-
tonin (5-HT), (C) IL-6, and (D) IL-4. BALB/c BMCMCs were cultured
without IgE or with ascites IgE at 0.005 or 5.0 mg/ml for 4 d. All values
are mean 6 SEM (n 5 3). (A–D) *P ,0.05, **P ,0.005, ***P ,0.0001
versus corresponding values for cells cultured without IgE. Compared
with values at 0 DNP–HSA for cells that had been incubated with the
same concentration of IgE for 4 d, significant (P ,0.01) release of 5-HT
first occurred at 1.0 versus 3 ng/ml DNP–HSA for cells incubated with
IgE at 5.0 versus 0.005 or 0 ng/ml, respectively. For IL-6 release, the cor-
responding values were 0.3 ng/ml DNP–HSA for cells incubated with
IgE at 5.0 or 0.005 mg/ml versus 1 ng/ml DNP–HSA for cells incubated
without IgE. Detectable release of IL–4 occurred at 3.0 ng/ml DNP–
HSA for cells incubated with IgE at 5.0 mg/ml, but not at all in cells incu-
bated with IgE at 0.005 or 0 ng/ml. Similar results were observed in an-
other experiment using IgE 2/2 BMCMCs.
Figure 5. Serotonin (5-HT) release from BMCMCs exhibiting differ-
ent levels of surface expression of FceRI, after challenge with various con-
centrations of either specific antigen (DNP–HSA) or the calcium iono-
phore, A23187. WBB6F1 1/1 BMCMCs were cultured without IgE or
with ascites IgE at 0.005 or 5.0 mg/ml for 4 d before passive sensitization
and antigen challenge or challenge with A23187. Zero in the A23187 ex-
periment refers to cells incubated without A23187 but in the highest con-
centration of vehicle used for these studies (DMSO at 0.1%). *P ,0.05,
**P ,0.001, versus corresponding values for cells cultured without IgE.
The data shown (mean 6 SEM; n 5 3 per point) are representative of the
results obtained in two separate experiments using WBB6F1 1/1 BM-
CMCs.668 IgE Enhances Mast Cell FceRI Expression
The effect of a 4-d incubation with IgE on the ability of
BMCMCs to release mediators in response to challenge with
IgE and antigen did not reflect a general enhancement of
the secretory responsiveness of the cells, in that there was
no significant parallel increase in the ability of the cells to
release 5-HT in response to stimulation with the calcium
ionophore A23187 (Fig. 5). The results shown in Fig. 5 are
representative of those obtained in two separate experi-
ments with BMCMCs and one with peritoneal mast cells.
The IgE-dependent Increase in Mast Cell FceRI Expression
Has Cycloheximide-sensitive and Cycloheximide-insensitive Com-
ponents. In RBL cells, the z50–90% increase in FceRI
surface expression that occurs as a result of incubation of
the cells with IgE for 4 h is insensitive to inhibition with
cycloheximide at 10 mg/ml (14). This, and other lines of
evidence, support the hypothesis that the modest change in
FceRI surface expression observed in this setting does not re-
quire protein synthesis but instead largely or entirely reflects
the reduced loss from the cell surface of FceRI that are occu-
pied by IgE (14, 15). In confirmation of these observations
with rat basophilic leukemia (RBL) cells, we found that in-
cubation of BMCMCs with cycloheximide (at 1, 3, or 10
mg/ml) had little or no effect on the roughly fourfold in-
crease in FceRI surface expression that occurred in the first
3 h after incubation of the cells with IgE at 5 mg/ml (Fig. 6
A). However, cycloheximide treatment profoundly sup-
pressed the subsequent, more sustained, increase in FceRI
expression by these cells (Fig. 6 A). Cycloheximide treat-
ment also resulted in a significant reduction in surface ex-
pression of FceRI in BMCMCs that were maintained in
culture without added IgE (Fig. 6 A). Similar results were
obtained in a second experiment.
Note that the cycloheximide-insensitive and cyclohex-
imide-sensitive components of the IgE-induced enhanced
surface expression of FceRI were detectable at relatively
early intervals after addition of IgE (3 h or 6–12 h, respec-
tively; Fig. 6 A), before the cells treated with cyclohexi-
mide began to exhibit substantially diminished viability, as
revealed by staining with Trypan blue (Fig. 6 B). More-
over, the effects of cycloheximide on FceRI surface expres-
sion were essentially identical in BMCMCs treated with the
drug at 1, 3, or 10 mg/ml (Fig. 6 A), whereas, as expected,
cells treated with higher concentrations of the agent exhib-
ited more toxicity at late intervals of culture than did those
treated with cycloheximide at 1 mg/ml (Fig. 6 B).
IgE Regulates the Expression of Mouse Mast Cell FceRI In
Vivo. We performed four experiments to investigate whether
IgE is an important regulator of mast cell FceRI expression
in vivo. In two experiments, affinity-purified mouse IgE
mAb (100 mg/day), or either affinity-purified mouse IgG2a
mAb (100 mg/day) or vehicle (PBS) alone, were administered
to BALB/c mice intravenously daily for 4 d, and peritoneal
mast cells were analyzed for FceRI by flow cytometry z18 h
after the last injection. Administration of IgE, but not IgG2a,
resulted in a greater than twofold enhancement of perito-
neal mast cell expression of FceRI (Fig. 7 A), whereas nei-
ther IgE nor IgG2a had any significant effect on mast cell
expression of FcgRII/III (data not shown).
Next, we assessed baseline levels of FceRI expression in
peritoneal mast cells of untreated IgE 2/2 versus IgE 1/1
mice, and found that FceRI expression was reduced by
z83% in mast cells from IgE 2/2 mice as compared with
those from wild-type mice (Fig. 7 B). We also found that
administration of IgE (but not IgG2a) antibody resulted in
a marked increase in FceRI expression by IgE 2/2 mouse
peritoneal mast cells (compare Fig. 7, B and C), whereas
treatment with either antibody had no significant effect on
mast cell FcgRII/III expression (data not shown). More-
over, there was a strong positive correlation, in the mice
shown in Fig. 7, A and C, between the log10 of the serum
Figure 6. Time course of changes in (A) the baseline or IgE-induced
levels of FceRI expression, and (B) cell viability, as assessed by Trypan
blue staining, of WBB6F11/1 BMCMCs cultured with or without
mouse IgE mAb (at 5.0 mg/ml) and with or without various concentra-
tions of cycloheximide (see Materials and Methods). All data are mean 6
SEM (n 5 3). (A) *P ,0.05, **P ,0.001, ***P ,0.0001 versus values at
the same timepoint for cells cultured with the same concentration of IgE,
but without cycloheximide; †P ,0.05, ††P ,0.001, †††P ,0.0001 versus
initial baseline (zero h) value. (B) Compared with values at the same time-
point for cells cultured with the same concentration of IgE, but without
cycloheximide, a significant (P ,0.05) reduction in cell viability first oc-
curred at 18, 12, or 6 h for cells cultured with cycloheximide at 1, 3, or
10 mg/ml, respectively. Similar results were observed in two experiments
using BALB/c BMCMCs or Cl.MC/C57.1 cloned mast cells (18).
Figure 7. IgE can regulate levels of peritoneal mast cell FceRI expres-
sion in vivo. (A) FceRI expression in peritoneal mast cells from BALB/c
mice that had been treated for 4 d with a daily i.v. injection of 100 mg of
affinity-purified IgE (n 5 7) or IgG2a (n 5 6) mAb, or vehicle (PBS)
alone (n 5 4). ***P ,0.0001 or ,0.005 versus values for PBS- or IgG2a-
treated mice, respectively. (B) Baseline levels of FceRI expression on
peritoneal mast cells from IgE 1/1 (n 5 8) and IgE 2/2 (n 5 7) mice.
***P ,0.0001 versus values for IgE 1/1 cells. (C) FceRI expression in
peritoneal mast cells from IgE 2/2 mice treated with purified IgE mAb
(n 5 5) or purified IgG2a mAb (n 5 4) as in (A). ***P ,0.0001 versus val-
ues for cells from IgG2a-treated mice. All values in (A–C) are mean 6 SEM.669 Yamaguchi et al.
IgE concentration at sacrifice and levels of mast cell FceRI
expression (R 5 0.871, P ,0.0001) (Fig. 8). And when
the peritoneal mast cells removed from the mice shown in
Fig. 7 C were tested for their ability to release 5-HT upon
antigen challenge in vitro, the response of mast cells from
mice that had been injected with IgE was markedly en-
hanced compared with that of the control cells from the
IgG2a-treated mice (Fig. 9).
Discussion
Exposure to monomeric IgE in vitro markedly upregu-
lated the ability of mature mouse peritoneal mast cells or
mouse BMCMCs or cloned mast cells to bind IgE. Two
separate lines of evidence indicate that this response largely,
if not entirely, reflected the increased surface expression of
FceRI. First, while mouse mast cells also express FcgRII/
III (17, 18), which can bind IgE immune complexes (18),
virtually all of the binding of monomeric IgE to mouse
mast cells that is detectable under the conditions used in
our experiments reflects binding of the ligand to a single
class of high affinity binding sites, i.e., FceRI (18). Second,
we used anti-IgE to immunoprecipitate surface-bound IgE,
and associated IgE receptors, from lysates of BMCMCs that
had been first incubated with or without IgE at 5 mg/ml for
21 h and then exposed briefly to excess IgE just before re-
covery for flow cytometry and Western blot analysis. We
found that, in comparison to aliquots of the same mast cell
population that had been incubated without IgE, mast cells
that had been incubated for 21 h with IgE exhibited an
z14-fold increase in IgE binding by flow cytometry and an
z17-fold increase in IgE- and cell surface–associated FceRI b
chain by Western blot analysis (Fig. 2 B). Thus, the IgE-
induced increase in IgE binding that was detected in BM-
CMCs by flow cytometry was directly proportional to the
amount of FceRI b chain obtained from anti-IgE immu-
noprecipitates of the same cells.
The IgE-induced changes in levels of mast cell FceRI
surface expression that were detected in our experiments
reflect the operation of two processes, which can be distin-
guished by their sensitivity to inhibition by cycloheximide.
In confirmation of the findings of Furuichi et al. with RBL
cells (14), we found that the earliest component of the IgE-
dependent increase in BMCMC FceRI expression (which
occurred within 3 h of addition of IgE) was largely resistant
to inhibition by cycloheximide. By contrast, virtually all of
the subsequent sustained, and striking, upregulation of FceRI
expression in these cells was ablated by cycloheximide. The
most straightforward interpretation of these findings, which
we favor, is that the initial, cycloheximide-insensitive, com-
ponent of the response reflects IgE-dependent suppression
of the loss of preformed FceRI expressed on the cell surface
(14, 15), whereas the sustained, cycloheximide-sensitive
component is more dependent on protein synthesis, e.g., of
new receptors.
To address the in vivo relevance of our findings, we per-
formed experiments in normal mice and mice that had been
rendered genetically IgE deficient. IgE 2/2 mice ex-
pressed baseline levels of FceRI that were 83% reduced
compared with those of normal (IgE 1/1) mice. Further-
more, both IgE 2/2 and normal mice exhibited significant
increases in the levels of peritoneal mast cell FceRI expres-
sion after i.v. treatment with IgE. These findings demon-
strate that IgE is a major regulator of mouse mast cell
FceRI expression in vivo. Indeed, analysis of data from the
IgE-treated IgE 2/2 mice and the IgE 1/1 mice that had
been treated with IgE, IgG2a, or PBS revealed a striking
positive correlation between the log10 of the serum IgE con-
centration at sacrifice and the log10 of the molecules of equi-
valent soluble fluorochrome (MESF) values for FceRI expres-
sion by peritoneal mast cells from the same mice (R 5 0.871,
P ,0.0001). Thus, our findings in mice directly support
the general form of the hypothesis that was originally pro-
posed by Malveaux et al. with respect to human basophils
(13), namely, that circulating levels of IgE can influence
levels of effector cell surface expression of FceRI.
Nevertheless, mast cells from IgE 2/2 mice exhibited
detectable, albeit greatly reduced, levels of FceRI on their
surface (Fig. 7 C), indicating that factors other than IgE
must also contribute to the regulation of mouse mast cell
FceRI expression. IL-4 has multiple effects that augment
IgE-dependent immune responses in mice; it is required for
normal IgE responses (30, 31) and can also promote the ex-
pansion of certain mouse mast cell populations (32, 33).
Moreover, peritoneal mast cells of IL-4 2/2 mice exhibit
fewer FceRI than do those of IL-4 1/1 mice (34). IL-4
can also upregulate levels of mRNA for the FceRI a chain
Figure 8. Correlation of se-
rum IgE concentration at sacri-
fice and surface FceRI expres-
sion of peritoneal mast cells in
the mice from the experiments
depicted in Fig. 7 (A and C).
The genotypes of the mice, and
the treatment which they re-
ceived (PBS, IgE, or IgG2a, i.v.
daily for 4 d) are depicted in the
symbol key in the figure. Note
that the correlation coefficient was
calculated based on all data except
those from IgG2a-treated IgE
2/2 mice, which were devoid
of serum IgE; as a result, n 5 22.
Figure 9. Upregulation of secretory
function of IgE 2/2 peritoneal mast
cells after administration of IgE in vivo.
Peritoneal cells were combined from
two of the IgE 2/2 mice that had been
treated with affinity-purified IgG2a
mAb and four of the IgE 2/2 mice that
had been treated with purified IgE mAb
from Fig. 7 C. IgE- and antigen-induced
5-HT release was determined for each
group of cells (n 5 3 per point) as in
Fig. 4 B. ***P ,0.0001 versus corre-
sponding values for cells from IgG2a-
treated mice.670 IgE Enhances Mast Cell FceRI Expression
in human eosinophils (35). We found that recombinant
mouse IL-4 (at 10 ng/ml) slightly enhanced peritoneal mast
cell FceRI expression over that induced by IgE alone, but
had little or no effect in the absence of IgE (data not
shown). In light of this finding, one may speculate that the
reduction in mast cell FceRI expression in IL-4 2/2 mice
might reflect, at least in part, the low levels of IgE in these
animals (31, 34).
One of the most significant aspects of our study is the
observation that changes in the concentration of IgE anti-
body not only can regulate the level of cell surface expression
of FceRI on mouse mast cells, but that this IgE-dependent
upregulation of mast cell FceRI expression is functionally
significant. This result was, in some respects, unexpected.
In their studies of human basophils derived from patients
with different concentrations of circulating IgE, Conroy et al.
(11) detected no significant differences in the histamine re-
lease responses induced by different concentrations of anti-
IgE in basophils from nonatopic donors, which expressed
as few as 3,900 IgE molecules/basophil, or allergic donors,
which expressed up to 500,000 IgE molecules/basophil.
Moreover, basophils from donors whose cells expressed ap-
proximately the same amounts of cell-bound IgE varied
greatly in their sensitivity to anti-IgE–induced histamine
release, perhaps reflecting a wide spectrum of intrinsic re-
leasability of human basophils derived from different indi-
viduals (11).
By contrast, we found that IgE concentrations can regu-
late the expression of FceRI by mouse mast cells within a
range that has significant consequences with respect to IgE-
dependent effector cell function. Compared with mast cells
that had been incubated with levels of monomeric IgE sim-
ilar to those present in the sera of some normal mice (i.e.,
0.005 mg/ml), mast cells that had been incubated with con-
centrations of IgE in the range observed in the sera of para-
site-infected mice (i.e., 5.0 mg/ml) exhibited significant
mediator release at lower concentrations of antigen and also
gave significantly greater release of mediators at given
higher concentrations of antigen. Thus, IgE-dependent up-
regulation of mast cell FceRI expression significantly en-
hanced both the sensitivity and the intensity of the secre-
tory response of the cells to antigen challenge.
This effect was especially remarkable with respect to cy-
tokine production. Thus, in comparison with cells that had
been incubated for 4 d with IgE at 0.005 mg/ml, BMCMCs
that had been incubated for 4 d with IgE at 5.0 mg/ml ex-
hibited z60% greater maximal release of the preformed
mediator, serotonin, but z6-fold greater release of the cy-
tokine IL-6 (Fig. 4, B and C). The effect of IgE incubation
on the ability of BMCMCs to produce IL-4 was even more
striking. Substantial IL-4 production in response to antigen
challenge was detected in BMCMCs that had been incu-
bated for 4 d with IgE at 5.0 mg/ml, but was not detectable
at all in cells that had been incubated for 4 d before antigen
challenge either without IgE or with IgE at 0.005 mg/ml.
The ELISA assay used for our studies has a lower limit of
detection of ,5 pg/ml of IL-4. It is possible (and perhaps
likely) that different conditions of passive sensitization be-
fore antigen challenge, or the use of more sensitive indices
of IL-4 production, may have permitted us to detect IgE-
dependent IL-4 production by BMCMCs that had not
been incubated with high concentrations of IgE for 4 d
before further passive sensitization and antigen challenge
(7, 36, 37). However, under the conditions employed in
our experiments, incubation of BMCMCs with IgE at 5.0
mg/ml for 4 d clearly markedly enhanced the ability of
these cells to release IL-4 in response to challenge with IgE
and specific antigen.
Taken together, our observations identify a novel and
potentially important mechanism for enhancing both the
sensitivity and intensity of IgE-dependent immune re-
sponses. Indeed, because IL-4 can markedly enhance the
generation of IgE responses in mice (30, 31), it is even pos-
sible that IgE-dependent upregulation of FceRI expression
by mouse mast cells, and subsequent enhancement of IgE-
and antigen-dependent mast cell IL-4 production, may con-
stitute a previously unrecognized positive feedback loop in
the expression of IgE-dependent immune responses.
While the regulation of IgE production is complex, po-
tentially involving multiple genetic and environmental fac-
tors, serum levels of IgE typically are greatly increased dur-
ing parasite infections and are also elevated in most patients
with allergic diseases (38–42). Our findings suggest that any
mechanism that results in the substantial elevation of IgE
levels may also result in significantly enhanced IgE-depen-
dent effector cell function. Furthermore, no matter what
may be the precise minimum number of cross-linked FceRI
that are required to trigger mast cell or basophil mediator
release (43, 44), cells that express increased numbers of FceRI
on their surface can be sensitized adequately with larger
numbers of different IgE species of distinct antigen specific-
ities. Thus, increased expression of FceRI by mast cells would
also permit each cell to be simultaneously sensitized to re-
spond to a larger number of different antigens.
In the context of acquired immune responses to parasites,
IgE-dependent enhancement of mast cell FceRI expression
would be expected to benefit the host. Unfortunately, the
same mechanisms might also increase the severity of allergic
diseases. Our preliminary experiments indicate that IgE can
also increase surface expression of FceRI on in vitro-derived
human mast cells (45). Accordingly, it will be of great in-
terest to assess to what extent IgE-dependent upregulation
of FceRI expression, as here identified in mouse mast cells,
also occurs in human FceRI1 cells, and, if so, to determine
whether the ability of IgE to regulate FceRI can be exploited
therapeutically in the management of allergic disorders.
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